Clinical trials
Advanced HIV Disease clinical trials
Below are recruiting advanced hiv disease clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05085171RecruitingPhase 3
Care plan to help reduce death risk in advanced HIV
This Phase 3 study tests an enhanced clinic care package for adults with advanced HIV to lower the risk of death. It may help by improving follow-up and treatment support for people who need closer care.
KampalaAges 18 years+ - NCT06904456Recruiting
Advanced HIV study in Zambia for those starting HIV treatment
This study looks at people with advanced HIV disease during their first months on antiretroviral therapy (ART). It aims to understand and improve care for those who start treatment when their immune system is weak.
LusakaAges 18 years+ - NCT07428577Recruiting
Tracking care for advanced HIV patients after hospital stay
This trial looks at whether staying in contact with patients after they leave the hospital helps them get better follow-up care. If you have advanced HIV and are in the hospital for a related illness, you may be able to join.
Johannesburg, GautengAges 18 years+ - NCT05580666RecruitingPhase 3
Lower death risk by adding azithromycin to HIV treatment
This Phase 3 study tests whether adding azithromycin helps people with advanced HIV disease live longer. You would start (or restart or adjust) HIV treatment within 4 weeks and may also receive azithromycin or a comparison approach to see if outcomes improve.
AbidjanAges 18 years+ - NCT06523608Recruiting
Predicting liver problems in advanced chronic liver disease
This study looks at people with advanced chronic liver disease to find ways to predict when they might get worse or develop liver cancer. Researchers hope to use this information to prevent complications and improve care.
Münster, North Rhine-WestphaliaAges 18 years+ - NCT06890637Recruiting
Fecal transplant and diet change for Crohn's disease
This trial tests whether a fecal transplant (putting healthy bacteria into your gut) combined with dietary changes can help control active Crohn's disease. It is for people who need stronger treatments or have stopped responding to their current therapy.
Kochi, KeralaAges 18–75 - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT07422675RecruitingPhase 1
Study of a new treatment for Parkinson's with motor fluctuations
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
Englewood, ColoradoAges 40–80 - NCT07209059RecruitingPhase 2
Nivolumab plus first-line therapy for advanced Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
MoscowAges 18–60 - NCT04066608Enrolling by invitation
Screening for advanced liver scarring in people with HIV
This study looks at how common advanced liver scarring (advanced fibrosis) is in people living with HIV. It may help doctors better understand liver risk in everyday care and guide future prevention.
MainzAges 18 years+ - NCT05422534RecruitingPhase 3
CoQ10 plus exercise for people with advanced kidney disease
This trial tests whether a supplement called CoQ10, along with supervised exercise, can improve how the body uses energy in people on chronic dialysis. It may help with muscle function and overall health if your heart and dialysis situation are stable enough.
Sacramento, CaliforniaAges 18–75 - NCT06791070RecruitingPhase 2
RC48-ADC plus immunotherapy for advanced scrotal Paget disease
This trial tests a combination of two drugs (RC48-ADC and JS001) for advanced scrotal Paget disease that has spread or cannot be removed by surgery. The goal is to see if this treatment can help shrink or control the cancer.
Fuzhou, FujianAges 18–80 - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT04150640RecruitingPhase 2
Chemo drug combination for advanced stomach or esophagus cancer
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
Madison, WisconsinAges 18 years+ - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06684327RecruitingPhase 2
Study of three chemotherapy drugs for rare advanced cancers
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07015684RecruitingPhase 1
Radioactive antibody and transplant for advanced sickle cell disease
This trial tests a radioactive antibody (131I-apamistamab) as part of conditioning before a stem cell transplant from a matched sibling donor. It aims to make the transplant safer and more effective for people with severe sickle cell disease.
New York, New YorkAges 12–50 - NCT06061276Recruiting
Combined therapy for large liver cancer with limited spread
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
Guanzhou, GuangdongAges 18–75 - NCT05414032RecruitingPhase 2
Using leftover DNA signals to guide treatment after head and neck cancer
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
TorontoAges 18 years+ - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06561555RecruitingPhase 2
Testing a new drug for advanced HER2-positive Paget's disease
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced HIV Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced hiv disease?
- Yes. Clin2 currently lists 46 recruiting advanced hiv disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced hiv disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced hiv disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.